Publication - Summary
Mar 01, 2017
Neuro-Oncology
January 22, 2021
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been identified as the causal agent of COVID-19 and stands at the center of the current global human pandemic, with death toll exceeding one million. The urgent need for a vaccine has led to the development of various immunization approaches. mRNA vaccines represent a cell-free, simple, and rapid platform for immunization, and therefore have been employed in recent studies toward the development of a SARS-CoV-2 vaccine. Herein, we present the design of an mRNA vaccine, based on lipid nanoparticles (LNPs)-encapsulated SARS-CoV-2 human Fc-conjugated receptor-binding domain (RBD-hFc). Several ionizable lipids have been evaluated in vivo in a luciferase (luc) mRNA reporter assay, and two leading LNPs formulations have been chosen for the subsequent RBD-hFc mRNA vaccine strategy. Intramuscular administration of LNP RBD-hFc mRNA elicited robust humoral response, a high level of neutralizing antibodies and a Th1-biased cellular response in BALB/c mice. The data in the current study demonstrate the potential of these lipids as promising candidates for LNP-based mRNA vaccines in general and for a COVID19 vaccine in particular.
Publication - Summary
Mar 01, 2017
Neuro-Oncology
Publication - Abstract
Aug 03, 2020
Vaccines
In this in vitro and in vitro study, the Yoshioka lab at Osaka University investigated cytosine–phosphate–guanine oligodeoxynucleotides (CpG ODN) lipid nanoparticles (LNPs) as an adjuvant for seasonal split vaccines (SV) from influenza virus antig...